Abraham H Hulst, Maarten J Visscher, Marc B Godfried, Bram Thiel, Bastiaan M Gerritse, Thierry V Scohy, R Arthur Bouwman, Mark G A Willemsen, Markus W Hollmann, Benedikt Preckel, J Hans DeVries, Jeroen Hermanides
AIMS: Most cardiac surgery patients, with or without diabetes, develop perioperative hyperglycaemia, for which intravenous insulin is the only therapeutic option. This is labour-intensive and carries a risk of hypoglycaemia. We hypothesized that preoperative administration of the glucagon-like peptide-1 receptor agonist liraglutide reduces the number of patients requiring insulin for glycaemic control during cardiac surgery. MATERIALS AND METHODS: In this randomized, blinded, placebo-controlled, parallel-group, balanced (1:1), multicentre randomized, superiority trial, adult patients undergoing cardiac surgery in four Dutch tertiary hospitals were randomized to receive 0...
April 2020: Diabetes, Obesity & Metabolism